[ Industry Watch ] CHINA Novartis Acquires Zhejiang Tianyuan to Expand Human Vaccines Presence in China ovartis had reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical NCo., Ltd. as part of a strategic initiative to build a vaccines industry Contact Details: leader in China and expand its presence in this fast-growing market segment. Novartis Corporation This proposed acquisition will require government and regulatory approvals Address: 608 Fifth Avenue in China. New York, NY 10020 As part of the collaboration, the two companies will work together to U.S.A. Tel: +1 800 277 2254 expand Tianyuan’s product portfolio and R&D pipeline through targeted URL: www.novartis.com investments in vaccines innovation, manufacturing technologies and commercial networks. This collaboration is also expected to facilitate the introduction of Novartis vaccines into China, where Novartis currently has a limited presence with an offering of vaccines against influenza and rabies. Contact Details: About Novartis Corporation Zhejiang Tianyuan Bio-pharmaceutical Address: Tianhe Road 56, Linping, Novartis is a world leader in the research and development of products to Yuhang District protect and improve health and well-being. The company has core businesses Hangzhou City, Zhejiang in pharmaceuticals, vaccines, consumer health, generics, eye care and animal Province health. P. R. China Tel: +86 0571 2628 6888 URL: www.ty-pharm.com About Zhejiang Tianyuan Bio-pharmaceutical Zhejiang Tianyuan is a privately-owned vaccine company offering a range of marketed vaccine products in China and R&D projects focused on various preventable viral and bacterial diseases. < 40 ■ Volume 13 > Number 12 > 2009 www.asiabiotech.com.